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Abstract
Although robot-assisted coronary artery bypass grafting (RA-CABG) has gained
more acceptance worldwide, its success still depends on the surgeon’s experience and
expertise, and the conversion rate to full sternotomy is in the order of 15% —25%. One
of the reasons for conversion is poor pre-operative planning, which is based solely on
pre-operative computed tomography (CT) images. This thesis proposes a technique
to estimate the global peri-operative displacement of the heart and to predict the
intra-operative target vessel location. The technique has been validated via both
an in vitro and a clinical study, and predicted the position of the peri-operative
target vessel location with ~ 3.5 mm RMS accuracy in the in vitro study while it
yielded ~ 5.0 mm accuracy for the clinical validation. As the desired clinical accuracy
imposed by this procedure is on the order of one intercostal space (10 - 15 mm), our
technique suits the clinical requirements. It is therefore believed that this technique
has the potential to improve the pre-operative planning by updating peri-operative
migration patterns of the heart and, consequently, will lead to reduced conversion to
conventional open thoracic procedures.
Key words: Image-guided cardiac surgery, Minimally invasive surgery, CABG, rigidbody registration, ultrasound, phantom study
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Chapter 1
Introduction

1.1 Coronary Artery Disease
Coronary artery disease (CAD) is one of the most common diseases worldwide.
In North America, CAD is the leading cause of death. For example, 44% of the
mortality and much of the morbidity in the United States is attributed to CAD [1].
The average life expectancy would increase by almost 7 years if all forms of CAD
were to be eliminated [2]. The costs related to cardiac disease is very high according
to the 2010 National Heart, Lung and Blood Institute which reported that CAD
costs patients $155.7 billion for medical care and $503.2 billion in direct and indirect
economic costs [3].
Except for a small number of patients, CAD is caused by a condition called
atherosclerosis, which occurs when fatty plaques or other substances are formed on
the walls of arteries and restrict normal blood flow. Since fatty plaques can be caused
by many different factors, there is no single cause of CAD. However, clinicians and
scientists have developed a set of “risk factors” that are measurable characteristics
that predict the probability of developing CAD. The next section will review some of
the risk factors which predispose to developing CAD.
1

1.1.1 Risk Factors
1.1.1.1 Lipoproteins
It has been established that low-density Lipoprotein (LDL) and high-density
Lipoprotein (HDL) cholesterol is closely linked to CAD. Increased LDL cholesterol
concentration increases the risk of CAD [4-6], while reduced HDL is also an indicator
of CAD [4, 7, 8]. Although the role of LDL has not been fully determined, most
researchers believe that its major role is in the formation of blood clots.
1.1.1.2 Blood Pressure
Blood pressure in patients is also an important factor in developing CAD. Mas
ter et al. have reported that patients who have increased blood pressure were more
susceptible to developing CAD and having a stroke [9]. Moreover, hypertension is as
sociated with insulin resistance, which may increase the risk of atherosclerosis through
other mechanisms [10].
1.1.1.3 Smoking
In a 2010 report, the latest from the U.S. Department of Health and Human
Services, the Surgeon General confirmed that smoking was an independent risk factor
for CAD [11]. Although it is not known exactly how tobacco increases the risk, one
of the effects of smoking is the acceleration of atherogenesis, which is the formation
of atherosclerosis. This indicated an increased risk for clinically manifested CAD.
1.1.1.4 Male sex
Being a male is one of the highest risk factors for CAD [12]. In the United States,
one in every three men younger than 60 develops CAD, in contrast to only one in
10 for women [1]. Although middle aged males have a higher risk of CAD, this risk
2

increases for post-menopausal women and the rate is eventually identical for both
sexes who are older than 60.
1.1.1.5 Diabetes
Beckman et al. [13] reported that patients with diabetes have a higher risk of
developing CAD. Many patients who have diabetes develop insulin resistance and
insulin resistance is found to be associated with decreased HDL cholesterol, increased
LDL cholesterol, as well as increased blood pressure [14].

1.1.2 Sym ptom s
Symptoms of CAD can vary from totally asymptomatic to fatal. However, the
most common symptom is chest pain or discomfort (angina). As atherosclerosis blocks
normal blood flow in the arteries, the lack of oxygen to the heart tissue, commonly
expressed as angina, is the result. Possible symptoms other than angina encompass
shortness of breath, fatigue during activity, acute coronary syndrome (ACS) or sudden
cardiac death. Patients with ACS are at high risk of cardiac muscle cell death in the
immediate future. Possible outcomes of cardiac muscle cell death are unstable angina
and myocardial infarction (MI).

1.2 Treatment Options For CAD
Below, we consider some treatment options for CAD.

1.2.1 M edication
Medication is a common option to prevent or reduce the further development in
the early stages of CAD. Although many factors contribute to the progression of CAD,
there are several biomarkers which indicate the severity of the disease. For example,
3

elevation of Myeloperoxidase (MPO) and LDL, and reduction of HDL are strong
indicator of the atherosclerosis. The following section will explain the three different
types of drugs which are commonly used to treat CAD : statins, beta-blockers, and
antiplatelet drugs.
1.2.1.1 Statins
Statins is the common name for the group of HMG-CoA reductase inhibitors used
to control HDL and LDL. As the literature reported, the development of CAD is
closely related to the level of LDL in the blood stream [15]. Statins work by inhibit
ing an enzyme called HMG-CoA reductase, which is responsible for producing LDL.
Among different cholesterol controlling drugs, statins have proven effective in reducing
cardiovascular morbidity and mortality in both primary and secondary prevention.
The role of primary prevention is to decrease the rate of heart attacks and strokes
for those who have not had any known cardiovascular diseases. Secondary prevention
refers to treatment administered to patients with pre-existing cardiovascular disease.
Waters et al [16] conducted the Canadian Coronary Atherosclerosis Intervention
Trial (CCAIT) and concluded that patients who have received Lovastatin (one of
the statins) experienced less progression of CAD compared with those who were
treated with a placebo. Another trial, Monitored Atherosclerosis Regression Study
(MARS), was also consistent with the reports from CCAIT [17]. Pravastatin, a
second statin, has also been shown to reduce the level of LDL. The Pravastatin
Limitation of Atherosclerosis in the Coronary arteries study showed that patients
who were treated with Pravastatin had a 40% reduction in LDL cholesterol level
and progression of atherosclerosis, compared with the control group who received
placebo [18]. Statins also have shown its effectiveness on MPO, which is an enzyme
that promotes atherosclerosis and acute coronary syndromes, with Ndrepepa et al [19]
reporting that the use of statins lowered the level of MPO by 20% compared to
patients without statin therapy.
4

Statins have been proven to reduce the risk of atherosclerosis through other means
other than controlling cholesterol levels. For example, Bellosta et al reported that
the use of statins can inhibit smooth muscle cell growth. Thus, these agent may
slow the progression of atherosclerosis [20]. In addition, Rosenson et al showed that
statins promote plaque stability through a combination of its lipid-lowering properties
and inhibitory effects on macrophage activation that consequently reduces the risk of
plaque rupture [21].
1.2.1.2 Antiplatelet Drug
As platelets are believed to play an important role both in the pathogenesis of
atherosclerosis and in the development of coronary thrombosis, antiplatelet drugs,
which inhibit the activity of platelets, are typically used on patients who have CAD,
with well proven benefits.
Antiplatelet drugs were first introduced to treat CAD in 1953 for protective pur
poses. Although there are many different antiplatelet drugs, aspirin and clopidogrel
are the ones which have been widely studied and most commonly used. The benefit
of aspirin was first reported in 1763, but in order to make this drug applicable for
CAD, it took much more time and it only recently became a therapy in CAD. The
use of aspirin was researched both for primary and secondary prevention. Research
on aspirin for secondary prevention is well studied and shows positive results in that
it improves clinical outcomes in patients with ACS, coronary artery bypass grafting
(CABG), and percutaneous coronary intervention (PCI) even though there is a risk
of bleeding. The Antiplatelet Trialists’ Collaboration conducted a study involving
135000 patients, with the following results: any serious vascular mortality was re
duced by 25%, non-fatal myocardial infraction by 30%, non-fat al stroke by 25% and
vascular mortality by 15% [22]. Moreover, the Canadian Antiplatelet Therapy Guide
line recommends a low dose of aspirin for patients who have undergone ACS, CABG,
PCI and cerebrocascular disease [23]. For primary prevention, however, the effective5

ness of antiplatelet drugs does not appear to be consistent, as some studies showed
the improvement of the outcomes [24] while other studies stated otherwise [25]. Gen
erally speaking, even with the benefits, there is major risk of bleeding from treatment
with antiplatelet drugs. Therefore, benefits are rather nullified or diminished and
other types of therapy are recommended.
Lastly, recent studies found that patients who have been treated with antiplatelet
drugs for long time do not respond to them and such situations have been termed “as
pirin or clopidogrel resistance”. This phenomenon could put patients in a dangerous
situation as Gum et al. [26] reported. Patients who have a resistance to aspirin have
a higher risk of myocardial infraction and death, compared with aspirin responders.
Therefore, even with the benefits of antiplatelet drugs, its use should be carefully
monitored.
1.2.1.3 /3-adrenergic blockers
/3-adrenergic blockers are so named as they inhibit /3-adrenergic receptors of
epinepherine and norepinipherine on the sympathetic nervous system, which are re
sponsible for increasing heart rate and vasocontraction. Since the /3-adrenergic blocker
was clinically introduced in 1962, it has been used for treating CAD and hypertension.
/3-adrenergic blockers have been used as the first-line therapy for hypertension
and its related diseases. For example, /3-adrenergic blockers significantly reduced
the risk of developing a stroke when compared with a placebo. Also, the patients
who were treated with /3-adrenergic blockers showed a 20% lower risk of having a
cardiovascular event compared to those on a placebo [27]. As a treatment for CAD,
/3-adrenergic blockers are typically used for secondary prevention rather than primary
prevention. Hawkins et al. [28] reported up to a 34% reduction in mortality with the
use of /3-adrenergic blockers to those patients who have had previous MI. Moreover,
sudden cardiac death was also reduced by up to 16% in patients who were taking /3adrenergic blockers compared to those on a placebo [29]. With these positive clinical
6

outcomes, ACC/AHA guidelines recommend that patients who have had MI take
/3-blocker therapy unless patients show a clear contraindication to the therapy [30].
The main limitation of /3-adrenergic blockers is, however, that its effectiveness on
primary prevention is still not clear. Moreover, like other types of medication, the
use of /3-adrenergic blockers is limited to preventing the progress of the disease and
to relieving the pain instead of curing the disease. These limitations force patients
who have severe CAD to undergo other types of treatment such as an intravascular
therapy or surgery.

1.2.2 Intravascular Therapy
Intravascular therapy is a non-surgical revascularization treatment for CAD which
uses a catheter to perform arterial dilation at the site of atherosclerosis. There are
two different types of PCI procedure dependent on how arterial dilation is performed:
i.e. with a balloon and stent. Balloon angioplasty was invented before stent angio
plasty and uses a balloon, which is placed in a catheter, to be inflated at the site
of atherosclerosis. On the other hand, a stent deployment leaves a metal frame to
support the arterial wall following inflation of the target vessel.
1.2.2.1 Percutaneous Transluminal Coronary Angioplasty
Percutaneous Transluminal Coronary Angioplasty (PTCA) was first performed on
coronary arteries in 1977 by Dr. Andreas Gruentzig [31]. After the success of the first
PTCA, it became an alternate treatment option to CABG surgery for atherosclerosis.
PTCA is a procedure used to increase the luminal size of the artery where blood
flow has been disrupted by atherosclerotic plaque, so that the normal blood flow can
be restored. For a typical PTCA procedure, a guide catheter containing a flexible
guide wire, a balloon catheter and contrast enhancing material for visualization, is
inserted into the femoral artery. Under fluoroscopic guidance, the guide catheter
7

advances to the ostium of the coronary artery to be dilated. Once the guide catheter
reaches its destination, the guide wire continues to advance to the stenosis and is
positioned in the distal arterial segment. The deflated balloon catheter then travels
through the wire and is positioned across the stenosis. The location of the guide wire
and the deflated balloon catheter is frequently confirmed by fluoroscopy with the aid
of intravascular contrast injected via the guide catheter. Once the location of the
deflated balloon catheter is confirmed, the balloon is inflated at a constant pressure
(usually 6 to 8 atmospheres). If the dilation of the stenosis is adequate in the view of
the surgeon, the guide catheter including the guide wire and the balloon catheter are
removed. If the desired dilation is not reached, the balloon catheter may be replaced
with one of larger diameter, while the guide wire continues to be held across the
stenosis.
Prom an efficacy point of view, about 90 percent of the non-occluded coronary
cases are performed successfully, which leads to effective relief of angina [32, 33].
Moreover, because of the nature of its non-invasiveness, PTCA is often considered as
an alternative treatment option for patients with recurrent angina who have under
gone CABG previously. However, PTCA appears less effective when the stenoses are
long, eccentric, or located at the ostium or the site of a branch point [34]. Patients
with unstable angina or advanced age might also have a lowered success rate.
A small percentage of patients who undergo PTCA procedures experience com
plications: 3% - 5% of patients have MI and 3% —7% require emergency bypass
surgery [35-37]. The death rate from PTCA is reported as 0% —6% [38, 39] while
2% —7% of patients experience acute or abrupt closure of the artery [36, 40]. When
the artery has a abrupt closure, an immediate revascularization (PTCA or CABG)
is required. For long-term complications, restenosis, the state when stenosis recurs,
frequently occurs in PTCA patients. Where the balloon dilates the lumen, damage to
the smooth muscle cells in the media may occur, leading to immediate platelet depo
sition or thrombus formation. Restenosis typically happens within six months after
8

the procedure and the rate of restenosis can be as high as 50% [41-43]. Restenosis
can be treated with a second PTCA treatment but the incidence of restenosis after
the second treatment is similar to that after the first.
When compared to medical therapy, PTCA gives patients an immediate relief from
angina and greater improvement in exercise performance [33]. However, compared to
medical therapy PTCA has a higher risk of MI and emergency bypass surgery [44].
Furthermore, PTCA might cause abrupt closure of the artery or restenosis. Although
PTCA has the benefits of rapid and complete relief of angina, many patients are first
treated with the medical therapy and proceed to PTCA or other revascularization if
the medical therapy does not work.
1.2.2.2 Stents
Due to PTCA’s high rate of restenosis as a result of the damage to the smooth
muscle cells or elastic recoil of the lumen, an alternative intravascular therapy is the
stent. The principal mechanism of a stent is almost identical to PTCA. However, the
difference between the two therapies is that stents place a metal frame after the aterial
dilation which is left inside the patient permanently, while PTCA uses a balloon as
an one-time therapy.
Although stents were first clinically used in 1986 [45], the use of stents began to
replace PTCA around 1994 [46]. Since then the use of a stent have become the primary
choice for intravascular therapy, because it reduces the risk of restenosis significantly
(about 25% —30%) compared to PTCA (around 50%) [47, 48]. It also reduces the risk
of the immediate need of revascularization, such as a second intravascular therapy
or surgery for abrupt vessel closure, since the metal frame stays inside the lumen
permanently. However, because stents introduce foreign material into the human
body, there is a chance the patient may develop thrombosis, the formation of a blood
clot resulting from the presence of foreign material in the blood stream. Thrombosis
usually leads to MI or death [49, 50]. To prevent this, patients who have undergone
9

stent surgery must take an antiplatelet drug for rest of their lives. Furthermore,
although the rate of restenosis is greatly reduced compared to PTCA, 30% is still
high and may require repeat intravascular procedures or surgery [51]. To overcome
these issues, researchers have tried different types of material to replace the metal
frame, such as inorganic elements (e.g. gold) or polymer (e.g. polyactic acid and
fibrin) [52, 53]. These attempts slightly decreased the rate of thrombosis , but the
rate of restenosis remained as high as 25% —30%.
Drug-Eluting Stents (DES) are an advanced type of stent, that was fully approved
by the Food and Drug Administration (FDA) in 2003 [53]. The metal frame in
DES is coated with an outer drug-loaded layer of polymer. This allows the right
amount of a drug to be placed at the site of stenosis to prevent restenosis. When
compared with bare-metal stent, DES shows improved results on the rate of restenosis.
Moreover, the Arterial Revascularization Therapies Study (ARTS) showed that the
rate of major adverse cardiac and cerebrocascular events (including MI, death, and
revascularization) is significantly lower than when using a bare-metal stent (15.9% vs
31.0%) and similar to that of CABG (16.4%) [54].
Among the many drugs which are in the trial process for their effectiveness,
sirolimus and taxol are currently available in clinical trials for DES. The rate of
restenosis for Sirolimus-eluting stent was as low as 2.3% compared to bare metalstent which was as high as 52.3% [55, 56]. Also, the rate of major adverse cardiac
event was reduced to 5.8%, versus 28.8%, for bare-metal stent [57]. Some literature
reported that Taxol-eluting stent reduced the restenosis rate to 5% from 25% for the
bare-metal stent [58, 59]. Even considering that many of these studies were conducted
with small sample sizes, they adequately showed the effectiveness of using DES over
the bare-metal stent.
Despite the success of DES, its chief limitation is found in repeat revascularization
mostly due to restenosis. Although some literature claims that the rate of restenosis
for DES is as low as 5%, the rate of repeat revascularization is still high when com10

pared to CABG (29.0%, 7.9%) [60, 61]. DES on patients who have diabetes appears
not to work as well as those without diabetes because the rate of stenosis and major
adverse cardiac events are much higher than CABG [54].
Finally, when stents are compared to medical therapy, one study shows that there
is no significant difference in the primary event rate, which includes death and MI.
However, about one third of patients who have been treated with medical therapy
requires revascularization due to unstable angina [62]. In conclusion, medical therapy
is optimal for those with stable angina but if patients have severe ischemia burden or
unstable angina, or they want to have immediate relief from their pain, stents should
be considered.

1.3 Coronary A rtery Bypass Surgery
CABG surgery is a surgical treatment of CAD. The chief goal of CABG is to
restore normal blood flow to the affected arteries, which were occluded by atheroscle
rosis. CABG is a revascularization procedure, where a bypass conduits is inserted at
the region distal to the site of the atherosclerosis to provide an alternative route for
blood. The first successful revascularization was performed in 1957 by Bailey [63].
With the invention of cardiopulmonary bypass (CPB), which immobilizes the heart
and halts its blood flow while shunting the pateint’s blood to a heart-lung machine,
and the coronary angiography, CABG has become a safe and solid treatment option
for those who have severe symptoms.
Due to the invasiveness of the surgery, great care must be taken when considering
undergoing such surgery. Patients with mild lesions are not usually recommended
for the surgery but instead are recommended other types of therapy such as medical
therapy or percutaneous artery intervention. Patients who have stable angina or
acute coronary syndromes are typical candidates for CABG procedure. The size of
the target vessel should also be more than 1.5 mm in order to maintain high patency
11

after surgery.
In conventional CABG, the chest of the patient is open (median sternotomy) and
the bypass conduit is harvested. The Saphenous vein or internal thoracic artery (ITA)
are commonly used as bypass conduits. The choice for the right conduit depends on
the location of anastomosis and the number of bypass. For example, ITA is usually
chosen over the saphenous vein because ITA has better patency and is free from
repeat revascularization. Fitzgibbon [64] reported that CABG using the saphenous
vein had 88% early vein graft patency, but decreased to 75% after 5 years and 50%
after 15 years, which may lead to re-operation. On the other hand, many studies
supported ITA as the choice conduit because of its long-term patency of over 90%
after 10 years [65, 66]. However, if patients requires more than three grafts, the
saphenous vein is usually employed after the use of both ITA (left and right).
Daement et al [60] reported that there is not much difference in the rate of
death, stroke or MI when CABG is compared to intravascular therapy. However,
repeat revascularization was significantly higher with stents, which could lead to a
significantly increased risk of adverse cardiac events. The cost of intravascular therpy
was 35% lower than that of CABG and with a better comfort level for patients
after the procedure, compared to CABG [67]. In conclusion, the main benefits of
intravascular therapy over CABG is the cost effectiveness of the procedure and the
reduced length of recovery. However, in the long run, CABG provides a clinical
freedom from repeat revascularization that intravascular therapy does not guarantee.

1.3.1 Off-pump CABG
Although an optimal surgical condition for CABG is achieved by using CPB, the
complications associated with the use of CPB are pulmonary, renal and neurolog
ical dysfunction, the risk of blood loss and transfusion and myocardial injury and
dysfunction [68, 69]. Moreover, patients with normal ventricular function generally
tolerate the use of CPB well for prolonged periods, but it could significantly increase
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the peri-operative mortality and morbidity rates if used on patients with depressed
ventricular function [70]. Therefore, CABG on the beating heart started to be con
sidered something to avoid in order to prevent the adverse effects from the use of
CPB.
CABG procedure with the beating heart is generally referred to as off-pump
CABG (OPCAB) and typically involves median sternomy. Unlike the conventional
CABG, however, a shorter incision is required for the OPCAB because it does not
need access to the ascending aorta, which is needed for a CPB. Since OPCAB deals
with beating hearts, greater experience with this type of surgery is necessary and
patients should be carefully monitored to increase the success rate compared to a
conventional CABG. Therefore, patients, for whom the use of CPB is a risk factor,
are optimal candidates. Such patients include the elderly, re-operative patients, or
those with renal or pulmonary dysfunction [71-73]. Although studies are limited with
small sample sizes, preliminary results show that OPCAB reduces complications asso
ciated with the use of CPB. Ascione et al [74] reported that blood loss was 1.6 times
higher with the on-pump patients compared with the off-pump patients. Also, only
23% of patients who underwent OPCAB needed a transfusion compared with 52% of
patient having the on-pump procedure. The same group showed that the myocardial
function was improved on patients with OPCAB [75]. Lastly, Plomondon et al [76]
claimed that the off-pump mortality and complication rates decreased from 4.0% and
14% to 2.7% and 8.8% respectively, when compared with the on-pump patients.
Although OPCAB requires a surgeon with more experience and expertise, it pro
vides an alternative for those who could not have undergone the conventional CABG
with good outcomes.

1.3.2 M inim ally Invasive CABG
Although OPCAB reduced the complications with the use of CPB, this type
of surgery is still limited by the requirement for a median sternomony. This may
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adversely affect patients with significant post-operative morbidity and discomfort. It
is now therefore possible to undergo a minimally invasive approach, which avoids
median sternotomy.
The first minimally invasive surgery was performed in 1967 by Kolessove, a Rus
sian surgeon [77], who performed internal thoracic artery grafts to coronary artery
anastomosis on a beating heart. However, his pioneer work was not appreciated un
til nearly 30 years later when it was revisited in the 1990’s with improved imaging
techniques. The procedure is called minimally invasive direct coronary artery bypass
(MIDCAB). MIDCAB is typically defined as a surgery without median sternotomy
but with small incisions between the patient’s intercostal space, and its less inva
siveness leads to a better post-operative function, fewer blood transfusions, a faster
recovery time, and shorter lengths of hospital stay [78-80]. However, because a sur
geon has only a limited view of the heart due to the small incisions, longer operating
and myocardial ischemic times have been observed, as well as target vessel misidentification may occur.

1.3.3 R obot-assisted CABG
Robot-assisted CABG (RA-CABG) is a variation of the minimally invasive ap
proach. While MIDCAB achieves a direct view of the heart from the incisions
made, RA-CABG fully depends on the visualization observed thorugh the a threedimensional stereo endoscope. Therefore, RA-CABG is also referred to as, totally
endoscopic coronary artery bypass (TECAB).
The da Vinci surgical system (Intuitive Surgical Inc., Mountain View, CA), the
only such system approved by the FDA, is employed in RA-CABG procedures. The
da Vinci system is composed of two parts: a master console and a slave robot. While
high-definition three-dimensional video visualization is offered from the endoscope,
the surgeon is situated in the master console and controls the slave robotic arms re
motely. At the patient table, three small incisions are made in the patient skin to
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Fig. 1.1: RA-CABG of left internal mammary artery on the left anterior descending
artery using da Vinci surgical system. Image courtesy of Maria Currie, London, ON
accomodate: the endoscope and the left and right robotic arms (Fig. 1.1). From
there a high-definition endoscope is inserted into the thoracic cavity via the fifth in
tercostal space, while the third and seventh intercostals are used for the right and
left robotic instruments respectively. Under the remote control of the surgeon, microsurgical instruments with 7 degrees-of freedom achieve high-precision, well-controlled
and wide-ranging movement at its tips. Also, thanks to the robotic system, any
unintentional movements from the surgeon are filtered.
RA-CABG can be performed either on pump, while the patient is connected to
the cardiopulmonary bypass, or off-pump, on the beating heart. Although Bonatti et
al [81, 82] reported that all their patients recovered without any major adverse car
diac or cerebral events following the on-pump RA-CABG performed on the arrested
heart, this approach may lead to complications, such as post-perfusion syndrome or
arrhythmia due to prolonged use of the CPB. To minimize these risks, many groups
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have adopted the off-pump RA-CABG approach [83-86], leading to approximately
25% increase in its use across North America [87].
Although off-pump RA-CABG is a new technique for revascularization, many
studies have been conducted to validate its efficacy. Srivastava et al [88] reported
that early patency of the graft is around 99% while clinical freedom from graft failure
reached 98.6%. Also, Gao et al [89] concluded that RA-CABG is a safe procedure
with an excellent early and midterm patency of anastomosis. Moreover, Argenziano
et al [90] reported that they achieved 91% of overall freedom from reintervention or
angiographic failure for RA-CABG on the arrested heart, and Falk [91] agreed with
the procedure’s safeness and efficacy.
As surgeons depend completely on the visualization of the 3D endoscope, the
experience and expetise is a must to perform a procedure safely. With the same
reason, they encounter a substantial learning curve. Moreover, although the number
of RA-CABG procedures are increasing, the cost of the surgical system is a major
factor preventing many institutions to employ it. Lastly, because of its short history,
the long term results of this procedure has yet to be validated.

1.4 M otivation
A major limitation of the robot-assisted technique is the need to convert to openchest surgery because of the difficulties associated with the access and manipulation
of closed-throacic surgery. The conversion rate has been reported to be in the range
of 15% —25% [92-94] and it has been primarily caused by the inability to access the
surgical target with the robotic instruments, lack of adequate workspace inside the
thoracic cavity and instrument collision.
In an effort to reduce the need for conversion, several groups have relied on ex
ploiting the pre-operative CT images routinely acquired prior to the procedures. Figl
et al [95] proposed a method to “highlight” the surgical targets in the endoscopic
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Fig. 1.2: (a) Pre-operative surgical planning based on pre-operative CT image, show
ing left anterior descending artery (red), robotic arms and intercostals space (yellow
lines); (b) US images of left lung deflation stage with the aortic valve and mitral valve
extracted; (c) The shift from left lung deflation (orange) to the thoracic insufflation
(gray) and their corresponding segmented valvular structures.
display of the da Vinci system by overlaying the pre-operative CT image onto the
real-time video. Unlike Figl et al, who used the pre-operative image as an intra
operative image guidance tool, Trejos et al [96] used the pre-procedural CT image to
identify the optimal port placement configuration that facilitates access to the targets
and prevents instrument collision during manipulation. To improve robustness, Falk
et al suggested a complete cardiac navigation platform that integrates both patient
and robot modeling and surgical planning, as well as an augmented reality overlay of
the pre-operative images onto the endoscopic view [97].
While these approaches rely on a surgical plan based on pre-operative data ac
quired days prior to the procedure, no attempts have been reported that use peri
operative information to update the pre-operative plan, to better reflect the intra
operative conditions. In order to ensure adequate space for instrument manipulation,
the procedure workflow of RA-CABG comprises two “invasive” processes - left lung
deflation and CO2 thoracic insufflation (see Fig. 1.2). As a result, the intra-operative
location of the heart and surgical targets may differ significantly from that depicted
in the pre-operative CT image. Thus, by not taking into account these migration
patterns, conversion may be required, as the planned access path to the target ves17

sel may be invalidated by the peri-operative heart displacement. Hartung et al. [98]
have proposed an image-guided approach which overlays the segmented left anterior
descending (LAD) artery — a typical surgical target for CABG procedures, onto the
endoscopic video by registering the pre-operative CT to the intra-operative stereo
image. Their study, however, was conducted via median sternotomy rather than in
a minimally invasive fashion, and hence the heart displacement induced via openchest access could exceed that induced by robot assistance. Thus, we propose a novel
method for acquiring peri-operative images of the heart using tracked ultrasound (US)
and predict the intra-operative location of the LAD by registering the pre-operative
CT data to the intra-operative US data. This approach has the potential to provide
an optimal port placement during pre-operative surgical planning and consequently
reduce the conversion to conventional CABG.

1.5 Thesis Contributions
The goal of this project is to improve the pre-operative surgical planning of RACABG by providing peri-operative migration patterns of the LAD through US-to-CT
registration. The specific objectives that must be met to achieve this goal are:
• Develop registration techniques which fuse intra-operative US images to pre
operative CT images.
• Conduct an in vitro validation study, in which clinically observed migration
patterns were simulated to assess and compare the accuracies of the registrations
• Conduct clinical validation study using offline data from patients who under
went RA-CABG.
• Measure the shifts of the heart induced by peri-operative interventions.
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1.6 Thesis Outline
This thesis is organized as follows:
Chapter 1 provided as an introduction to the clinical background of coronary
artery disease to provide a context for the motivation of the work to be presented
in the remainder of this thesis. The pathophysiology and the treatment of coronary
artery disease as described, as well as the different types of CABG techniques.
Chapter 2 introduces image-guided surgery and its current status. It presents
and discusses the registration technique, which is a crucial part of image-guided
surgery. It also introduces the rigid-body registration algorithms that were devel
oped as part of this thesis’ work.
C hapter 3 is a description of the in vitro validation experiments performed on a
beating heart phantom to assess the accuracy of the registration techniques.
Chapter 4 presents a clinical validation as well as the clinical applications of the
registration. Offline patient data were employed for the clinical validation following
simulations. The migration patterns of the heart, which were induced by interventions
in RA-CABG, were also observed.
Chapter 5 presents conclusions and explores future directions. A discussion is
presented on how the pre-operative surgical planning of RA-CABG can be enhanced
by updating the migration patterns of the heart and how the registration technique
can be extended into other types of cardiac surgeries.
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Chapter 2
Image Registration
Since the development of the x-ray by Roentgen in 1895, medical imaging has since
significantly improved and been extended for other types of imaging such as US, CT,
magnetic resonance (MR) images, positron emission tomography, and single-photon
emission computed tomography. Nowadays, many procedures employ more than one
type of imaging modality and the role of imaging is no longer limited to finding a
lesion before a procedure, but is actively employed intra-operatively to improve the
outcome of the procedure, i.e., image-guided surgery. To obtain maximum bene
fits from multiple modalities, it is important to fuse different modalities effectively.
Registration is one way to fuse images within a single frame. This chapter will re
view the current techniques of registration in medical imaging and the mathematical
explanation of “rigid-body” registration, which was employed in our project.

2.1 Image R egistration in surgeries
As explained above, imaging is used to visualize important anatomical features,
either pre- or intra-operatively. However, each imaging modality has different usages
during the course of the procedure. Thus it is important to show the changes in
various anatomical features between different stages of the procedure within the same
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modality, as well as between different imaging modalities. Image registration plays
a key role in the detection of change between stages by aligning one set of images
to another. US imaging is commonly used intra-operatively bacause of its unique
ability to acquire images in real-time, while other modalities such as CT or MR
images are typically taken in pre-operative stage. However, the lack of detail from
US requires registration to CT or MR images, which provide more image details
and anatomical features. Image registration from CT, MR or fluoroscopy to US has
been reported by many groups such as Huang et al [99] who registered 2D US to
3D CT to provide high quality details of the beating heart. Also, Gobbi et al [100]
overlaid intra-operative US images onto a pre-operative MR image in stereotactic
neurosurgery to gain better visualization during the procedure, while Linte et al [101]
registered subject-specific models, segmented from MR images, to intra-operative US
images in order to create a virtual reality environment for image-guided mitral valve
surgery. Recently, Lang et al [102] registered fluoroscopy to US images to improve
visualization during percutaneous aortic valve replacement surgery.
Image registration is widely used in medical imaging research, in fields such as
neurosurgery [103-106], radiotherapy [107, 108] and cardiac surgery [109-111], and
many different registration algorithms such as rigid-body registration and non-rigid
registration have been developed to meet the needs of the different cases outlined
above. Among these different techniques, we focus solely on rigid-body registration
in this thesis.

2.2 R igid-body Registration
The rigid-body registration problem can be formally stated as an approximation
problem. Given two different datasets (usually images or sets of points), rigid-body
registration aligns them so that important spatial features are matched between the
datasets by applying a simple transformation. While the datasets can have different
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dimensions depending on images (typically 2D or 3D), rigid-body registration has six
degrees of freedom (DOF) in three dimensions (3D), which specifies the translation
and rotation required to align the images. Note that rigid-body registration some
times implies registration which includes rigid-body, similarity, and affine registration.
Similarity transformations comprise translation, rotation and anisotropic scaling (9
DOF), while affine transformation has an additional shearing transformation on top
of the similarity transformation (12 DOF). In this thesis, “rigid-body” registration is
defined to be a simple 6 DOF registration. In the following two sections, two different
rigid-body registration techniques are discussed.

2.2.1 Point-based Registration
Registration algorithms use different types of constraints. The types of rigid-body
registration can typically be divided into two classes, landmark-based and intensitybased. Given two image datasets, intensity-based registration does not require dataset
segmentation for feature extraction, but rather uses correlation metrics on the inten
sity patterns in the datasets to perform the registration. Therefore, it is important to
know what imaging modalities are being used prior to registration, as intensity-based
registration employs different voxel measures for registration processes compared to
point or feature based. Generally speaking, registration can be employed on the same
modalities (intramodality) or different modalities (intermodality). For intramodality
registration, the sum of the squared intensity difference can be used as a registration
quality metrics, while mutual information or normalized mutual information may be
preferred for intermodality registration.
In point-based registration, on the other hand, it is the identification of homolo
gous features in each image that is important. Feature extraction can be performed
manually or automatically, and the points collected are called fiducial markers or
fiducial points. Once the desired anatomical features have been extracted from the
datasets, the registration then discards the original datasets and proceeds with just
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the point sets defining the features for further processing. While point-based regis
tration may be performed in 2D to 3D or 3D to 3D, for the purpose of our discussion,
point-based registration will refer to 3D to 3D only. Given two equal sized sets of
points, p, the moving points, and q, the fixed points, point-based registration becomes
the problem of finding the least squares rigid-body transformation which minimizes
the Euclidean distance between the two point sets. To achieve this, one computes a
translation vector, t, and a rotation matrix, R, that minimizes:
N
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( . )

where N is the number of points.
Pseudo code for the registration process is given below:
(1) Find the centroid (center of mass) of each data set
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( . )

(2.3)
t—l

(2) Compute the displacement between the centroid and each point in the data set.
P = Pi - P
q= qi-q

(2.4)
(2.5)

(3) The minimization problem becomes:
N
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( . )

R can be found by minimizing e2 and then computing t = q — i?p.
This least-squares estimation problem has a closed-form solution and so does not
require an iterative solution method. Horn’s method using unit quaternions [112] and
a singular value decomposition (SVD) [113] is commonly used for this procedure (see
Appendix A).
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2.3

Surface-based Registration

Surface-based registration is similar to point-based registration in that it also
requires feature extraction from image datasets. While point-based registration is
restricted to using homologous points, which are the corresponding points on both
images that should represent the same ordered features, surface-based registration
has more freedom in terms of the types of constraints used because surfaces can be
defined as a simple point set, faceted surface, implicit or parametric surfaces. The
variety of constraint choices allows this registration to be used widely in image-toimage (CT, MR or other modalities), or physical-to-image registration (i.e., bone
to image). Surface-based registration is employed when the number of homologous
point pairs is insufficient for robust registration. The skin boundary surface, any
bone structure or any other surfaces with high contrast are good candidates for this
registration.

2.3.1 Iterative Closest Point
There are many registration algorithms available for surface-based registration,
such as Head and Hat or Disparity functions. However, the iterative closest point
(ICP) algorithm is one of the most widely used algorithms. ICP was first introduced
by Besl and McKay [114] and finds the best transformation between two datasets
by reducing the general nonlinear minimization problem to an iterative point-based
registration problem. While ICP can be used in various representations as described
above, point sets and triangle sets are the most common representations, since many
segmentation algorithms in medical imaging extract features in this manner.
Given the source and target datasets (i.e. images), the steps involved in ICP are:
(1) An initial registration (i.e. a simple rigid body registration) is applied to the
source dataset so that the two datasets align relatively close to each other.
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(2) Place the source dataset into a ¿-dimensional (kD) tree.
(3) Each target point finds its closest Euclidean distance source point from this kD
tree.
(4) Using these target and closest source point sets, perform point-based registration.
(5) Find the residual from the transformation to describe the quality of the match.
Steps 2 to 4 are repeated until the algorithm satisfies the termination criteria
based on the difference between two adjacent registration residuals being smaller
than some threshold (user defined). The initial transformation can be performed in
many different ways, such as using several landmarks for the registration. As ICP is
sensitive to the initial registration, it is important to first accurately align the source
and target datasets before any processing is further done.

2,3.2 Robust Statistics
A potential problem with using the original ICP algorithm is that its accuracy may
be compromised when the data contain erroneous measurements, since ICP weighs
every point equally. However, since the data was obtained by a manual segmentation
(the features are defined manually rather than computed), it is inevitable that it
contains some points that are not as accurately aligned as others. Removing outliers
during the registration process could greatly improve its accuracy and some types of
robust estimator are widely employed to achieve this.
There are various different types of robust estimators and one way to characterize
them is to compare the gross-error sensitivity, meaning how well a certain estimator
responds to various ranges of error.
For example, the least-squares estimator has an unbounded gross-error sensitivity
since it will include any point, no matter how large the errors are. This estimator,
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therefore, is not suitable for outlier detection. For this reason, the gross-error sensi
tivity of most robust estimators is bounded, and different estimators have different
means of setting the bounds on the gross error. The influence function (how outliers
are weighed) is commonly used to visualize the gross-error sensitivity.
Three influence functions are shown in Fig. 2.1. As the above described, the leastsquare estimator demonstrates a linear behaviour without bound, while Lorenzian’s
and Tukey’s biweight influence functions start decreasing the influence of outliers at
a certain point. Given that different functions behave differently, a robust estimator
should be chosen carefully based on the application.
Once the right estimator has been chosen, it is also important to determine the
rejection point for a given dataset and a scale parameter is used to determine a proper
rejection point. A standard scale parameter for a robust estimation (a) is the median
absolute deviation (MAD), as shown in Equation (2.7) below:
a = c- mediarii {|Xi —mediarij {xj}\} .

(2.7)

The constant c is designated for optimizing a value of the estimator to a particular
distribution. For example, if the distribution is a zero-mean normal distribution,
constant c could be 1.4826 to cover one standard deviation of the population.

2.3.3 Robust ICP
Our robust ICP algorithm was originally adopted from Ma [115]. The principle of
robust ICP is to perform weighted ICP, where the weights are determined by a robust
estimator. To integrate the weights in ICP, Horn’s method is preferred over SVD,
because using weights in Horn’s method has already been described in his algorithm
(i.e. Tukey’s biweight), while SVD does not provide any straightforward way to use
the weights. Therefore, for each iteration of ICP, the scale of the robust estimator
is computed based on residual errors of the dataset and consequently outliers are
discriminated against while weights are assigned to the remaining data points. A
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Fig. 2.1: Influence function of (a) least-squares error norm, (b) Lorentzian error norm
and (c) Tukey’s biweight error norm.
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pseudo code for Robust ICP is provided in the Appendix B, which was adopted
from Ma [115].

2.4 Evaluation
The purpose of registration is to align two different images of anatomical features
within the same view, to observe the changes between two stages and to enhance the
detail of the features. Maintz and Viergever [116] recommeneded ways to evaluate
registration, such as precision, accuracy, robustness, resource requirements, algorithm
complexity, assumption verification and clinical use. However, this section will focus
only on the quantitative accuracy of aligning two image datasets as an assessment of
reliability, and not on patient outcome. As discussed by [117], there are two measures
used to define accuracy of the registration algorithms:
1. target registration error (TRE) and
2. fiducial registration error (FRE).

2.4.1 Target R egistration Error
Target registration error is the most important alignment measure when speak
ing of registration accuracy. The term “target” has been used to differentiate it
from “fiducials”. As explained in Section 2.2.1, fiducial points are those used for
registration purposes. They are usually chosen based on their visibility in different
modalities. As a result, they are usually not clinically relevant anatomical features
but rather salient points such as bright spots on images, vascular junctions etc. How
ever, unlike fiducials, targets are anatomical features or regions the surgeon is looking
for in the procedure or during diagnosis. As a result, TRE is the most meaningful
of the error measurements. Given that p and q represent target points in the first
and second image datasets respectively, TRE can be found using T, a transformation
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computed from evaluating a registration:
TR E = \\T(p)-q\\2.

(2.8)

2.4.2 Fiducial R egistration Error
Fiducial registration error is a measurement based on the points which have no
significant clinical meaning, but are used for registration only. When fiducials are de
fined either manually or automatically, there may be errors associated with localizing
them. This type of error is called fiducial localization error (FLE) and because FLE
always occurs before registration is performed, FLE affects both the FRE and TRE.
The presence of FLE means that FRE cannot be used as an estimate of TRE because
it may cause either an underestimation and an overestimation of FRE. Underesti
mation occurs when a value of FRE is lower than the value of TRE. This happens
because a registration attempts the best to find the best transformation to match the
fiducials. When actual fiducials are incorrectly defined in the same manner in one
image dataset, it will yield low FRE because the registration tries to align fiducials as
close as possible. However, this will lead TRE to be greater since the error in localiz
ing fiducials adds onto the TRE. For example, if the FLE on one image dataset is 1
mm in the x direction while the FLE on another dataset is 2 mm in the y direction,
the registration would result in a FRE of 0 but a TRE of 2.2 mm (\/l2 + 22 « 2.2)
because of the FLE (see Fig. 2.2).
Secondly, overestimation occurs when the value of FRE is higher than the value
of TRE, when the error on each fiducial is not defined in the same manner to each
other, but with a different magnitude and/or direction. The end result could be that
TRE is small after the registration but FRE would be larger compared to TRE, which
concludes that FRE overestimates TRE. For example, half of the fiducials have an
error of +1 mm in the x direction while the other half have an error of -1 mm in the
x direction. In this case, FRE will yield 1 mm while TRE will continue to be zero
29

F IE * -1 mm in x direction

cm

□
□

Tru e position of fiducial
Localized position of fiducial
Tru e position of target

o

□
Image after registration

Image 2

Image 1

§

□

☆

□

o*
a)

FRE * 0 mm
TRE 3 2.2 mm

cm

☆

o#

FLE 3 2 mm in y direction

□

b)

■

9

Tru e position of fiducial
Localized position of fiducial
Tru e position of target

C)

Fig. 2.2: Schematic of underestimation: (a) Fiducials are localized with FLE of -1
mm in x direction on the first image, (b) Fiducials are localized with FLE of 2 mm
in the y direction on the second image and (c) registration yields 0 mm of FRE while
2.2 mm of TRE due to underestimation
(see Fig. 2.3). Lastly, Fitzpatrick [118] has shown that TRE and FRE are actually
uncorrelated mathematically and experimentally via computer simulation. Although
FRE values are much less than TRE in general, FRE could still be a good measure
to evaluate the registration results because FRE is easier to compute than TRE and
measuring FRE could be a good means of validating the quality of the registration.
FRE is typically reported as a root-mean-square (RMS) calculation as follows:
FRE2 = J2 \T (P i)-q i\2.

(2.9)

2.5 Summary
As different modalities are being used in an image guided surgery, it is crucial
to have a good registration between source and target image datasets. This chapter
explained rigid-body registration, with a focus on landmark based registration. While
there are many types of rigid-body registrations available, our work focuses on a
modified ICP algorithm, which is a type of surface-based registration which uses
Tukey’s biweight statistical estimator. Moreover, we have discussed the evaluation
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Fig. 2.3: Schematic of overestimation: (a) Half of the fiducials are localized with FLE
of-1 mm in the x direction while others are localized with FRE of 1 mm in x direction
on the first image, (b) Fiducials are localized with FLE of 0 mm on the second image
and (c) registration yields 1 mm of FRE while 0 mm of TRE due to overestimation.
measures (TRE and FRE) to assess the accuracy of the registration. The following
chapters explore how the registration discussed in this chapter may be implemented
in image-guided robot assisted CABG procedures.
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Chapter 3
Phantom Validation

3.1 Introduction
As discussed in the motivation of the project, the intra-operative imaging modality
(i.e. 2D Trans-esophageal echocardiography) is not able to identify the surgical target
vessel under the current RA-CABG setting. To bypass this issue, registrations that
involves the anatomical features as contraints, which are visible on both pre-op CT
and intra-op Trans-esophageal echocardiography (TEE), were developed. As a initial
step toward a full validation, we conducted an in vitro study using a realistic heart
model.

3.2 M aterials and M ethods
3.2.1 Clinical Procedure Workflow
In a typical robot-assisted CABG procedure, a pre-operative CT image of the
patient is acquired for surgical planning (Stagecr). To ensure sufficient work space
inside the closed-chest, during the procedure, the patient undergoes several “inter
ventions” consisting of intubation and anesthesia delivery (Stageo), deflation of the
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left lung (Stagei), and thoracic insufflation (Stage2). To illustrate how pre- and
intra-operative imaging is used to obtain measurements of the heart migration dur
ing the RA-CABG procedure, we follow a hypothetical patient through the proposed
workflow.
3.2.1.1 Image Acquisition
A cardiac-gated CT image of the patient’s thorax depicting the heart at mid
diastole is acquired as part of a routine pre-operative exam for a patient undergoing
RA-CABG. Since the images are acquired with contrast enhancement, they provide
reliable information with regards to the shape and location of the major vessels,
including the LAD.
During the robot-assisted procedure, 2D TEE is used to acquire images of the
patient’s heart at each stage of the peri-operative workflow using a Philips SONOS
7500 scanner (Philips, Andover, MA). While TEE is the standard imaging modality
for cardiac monitoring during interventions, for this application, the image acquisition
is spatially tracked using a modified TEE transducer [119]. Surgical tracking technol
ogy has become indispensable in image-guided interventions, as it allows surgeons to
identify the position and orientation of the instruments and visualize them relative to
the anatomy and surgical targets. In spite of the high localization accuracy achieved
using optical tracking technology [120], this application favours magnetic tracking
since no direct line-of-sight can be established between the TEE probe inserted in the
patient’s esophagus and an optical tracking camera mounted overhead. As a result,
the NDI Aurora (Northen Digital Inc., Waterloo, ON, Canada) magnetic tracking
system is employed; the TEE transducer is tracked via a 6 DOF sensor embedded
inside the casing of the probe, while another 6 DOF single disc marker is attached
to the patient as reference. Using the magnetically tracked probe, US images of the
patient’s heart are acquired from different views to depict several features of interest
at each peri-operative workflow stage.
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St 1: Dual-lung vent.

St 2: Single-lung vent.

St 3: Chest insufflation

Fig. 3.1: Graphical representations of the peri-operative heart shift during RA-CABG
procedure: (a) after intubation and anaesthesia (red) (b) after left lung deflation
(green), and (c) after chest insufflation with CO2 (blue)

3.2.2 Estim ating Peri-operative Heart M igration
In a previous investigation [109], the migration of the heart was studied in four
patients using a feature-based registration technique that relied on the mitral and
aortic valve annuli to describe the location of the heart. Preliminary data have
shown that the heart undergoes substantial displacement following lung deflation
and thoracic insufflation, resulting in changes in position on the order of 25 —35 mm
between the pre- and intra-operative conditions (Fig. 3.1).
We also have observed from the same study that the morphology of the valvular
structures (i.e. length of short and long axis, valve annulus perimeter and intervalvular distance) remains relatively unchanged throughout the workflow, despite
considerable displacement of the heart. Based on the suggested conclusions that
no significant non-rigid deformations occurred, our aim is to improve the currentlyemployed feature-based rigid registration by adding additional constraints near the
base and apex of the heart, to yield optimal alignment along the surgical target - the
LAD coronary vessel.
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3.2.2.1 Predicting Target Vessel Location
Since the LAD can only be identified in the pre-operative CT image and not in
the peri-operative US images, its intra-operative location must be inferred from the
pre-operative data. Therefore, four anatomically relevant features that can be easily
identified from both CT and US are used to assist in the pre- to intra-operative
registration: the left coronary ostium (LCO), the mitral valve annulus (MVA), the
aortic valve annulus (AVA) and the left ventricular apex (LVAp). The LAD begins
at the LCO and typically runs toward the LVAp, while the MVA and the AVA are
located on either side of the staring point of the LAD. The MVA and the LVAp are
captured from a mid-esophageal-4-chamber-view at 20° increments from 0° to 180°,
while the AVA and the LCO are viewed from five long axis view images with 10°
increments, and one short axis view of the aorta at 30°. These features are manually
defined by an expert anesthetist on both CT and US images using a custom-developed
feature extraction tool: the MVA and the AVA are delineated as rings while the LCO
is identified as a point, and the LVAp as a paraboloid. Lastly, the path of the LAD
is also traced on the pre-operative CT dataset.
3.2.2.2 Pre- to Intra-operative Feature-based Registration
Two rigid-body registration algorithms that employ the four anatomical features
were investigated in this work: the first treats the extracted features as single land
marks with empirically-assigned weighting factors, while the second relies on a mod
ified ICP approach to align the four features in the homologous datasets.
Weighted Landmark-based Registration: After the four anatomical features
— the LCO, MVA, AVA and LVAp — are identified in the pre- and peri-operative
datasets, as a means to reduce the variability associated with their manual segmenta
tion, the features are treated as single landmarks, as follows: the LCO, the centroids
of the mitral (MVA) and aortic (AVA) valve annuli, and the vertex (i.e.global mini35

mum) of the LVAp segmented surface. Moreover, treating these features as landmarks
had the added benefit of reducing processing time.
Simple landmark-based registration was performed using the four landmarks, fol
lowed by the minimization of the Euclidean distance between the LCO and LVAp
using downhill simplex optimization [121]; these two features — LCO and LVAp,
were selected as the primary constraints for the registration given they bound the
superior and inferior ends of the LAD.
Robust ICP-based Registration: The second registration technique employed
the complete geometry of the anatomical features consisting of the LCO, two 3D
closed curves describing the MVA and AVA, and a parabolic structure defining the
“cap” of the left ventricular apex. For better accuracy, a virtual surface model of the
left ventricle apex was generated from the pre-operative CT dataset along with the
intra-operative features.
The robust ICP-based approach is an extension of the traditional ICP algorithm
employing Horn’s method to compute the registration transform [112, 114], with the
addition of a robust estimation technique [115]. The purpose of the robust estimator
is to reduce the effect which outliers within the datasets — in this case resulting from
inconsistencies in the extracted features due to manual segmentation — may have on
the overall registration. Based on different robust estimators which were discussed in
2.3.2, Tukey’s biweight is the best option for our project as it is considered to provide
reasonable performance across a wide range of three-dimensional data [115]. The
robust estimator assigns weights to each point based on the residual error between
the registered source and target points after each iteration, and it also effectively
discriminates against outliers whose residual error exceed a certain value by assigning
them zero weights [122]. The estimated weights are then used in Horn’s method to
compute the transform.
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3.2.3 In vitro Experim ental Validation
3.2.3.1 Experimental Apparatus
The in vitro study was conducted on a heart phantom (The Chamberlain group,
Great Barrington, MA, USA) and the apparatus was set up in a similar configuration
to that observed in the operating room (OR). Heart migration patterns similar to
those observed in our preliminary clinical study [109], were simulated in vitro by
changing the position and orientation of the phantom to mimic the observed peri
operative displacements. Sixteen CT-visible fiducials were attached to the surface of
the heart phantom: ten were used to perform the physical-to-image space registration
and the remaining six were used to outline the LAD path (Fig. 3.2a). The position
of the heart phantom was tracked throughout the experiment using a 6-DOF NDI
magnetic sensor attached to the phantom, while another 6 DOF single disc marker
was rigidly attached to the table to serve as global reference.
3.2.3.2 Image Acquisition
A pre-operative CT image of the phantom was acquired on a GE 64-slice LightSpeed VCT scanner with the voxel size of 0.49 mm x 0.49 mm x 0.63 mm (General
Electric, Milwaukee, WI, USA) and a virtual model of the phantom was generated
using automatic segmentation tools available in ITK [123].
Peri-operative US images of the phantom were acquired using the magnetically
tracked TEE probe described in 3.2.1. The position and orientation of the phantom
was changed twice to simulate the lung deflation and thoracic insufflation; the four
features - LCO, MVA, AVA and LVAp - were imaged three times at each of the three
workflow stages, and also the entire protocol was repeated three times to minimize
human error.
Once all the images were collected, the features were extracted using a customdeveloped segmentation tool. All features were defined in the same 3D coordinate
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Fig. 3.2: (a) An heart phantom image showing the LAD path; and (b) Peri-operative
US image acquisition protocol showing imaging of the apex and coronary ostia using
incrementally tracked 2D US images.
space: the LCO was identified as a single marker, the MVA and AVA were segmented
as 3D “rings”, and the LVAp was segmented by manually tracking the epicardial
contours of the apex in each of the 2D US images (Fig. 3.2). Lastly, the location
of the LAD vessel was also delineated on the pre-operative CT image using the six
fiducial markers, while its peri-operative location would be inferred using the proposed
registrations techniques.
3.2.3.3 Computing LAD Target Registration Error
The six fiducials that marked the LAD path were used to assess the TRE between
the predicted LAD location and its gold-standard location at each stage in the workflow. The gold-standard locations of the LAD fiducials were determined by recording
their positions at each stage using a magnetically tracked pointer. The predicted
LAD location was identified by applying the registration transform computed from
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Table 3.1: LAD TRE: Mean ± SD and RMS (mm) in in vitro study
Stages Robust ICP-based Weighted landmark-based
RMS
to CT Mean ± SD RMS Mean ± SD
3.7
2.1
3.3
±
1.7
2.0
±
0.7
Stage0
4.6
4.1 ± 2.1
3.3
Stagei
3.0 ± 1.2
5.3
4.7
±
2.4
2.6
2.5
±
0.8
Stage2
4.6
4.0 ± 2.2
2.6
Overall 2.4 ± 1.0
the registrations described in 3.2.2.2 to the pre-operative LAD fiducials.

3.3 R esults
In this experiment, three peri-operative RA-CABG procedure workflows were sim
ulated. For each of these nine poses, we acquired three sets of tracked US images,
defined the features of interest and used the two different proposed registration al
gorithms (weighted landmark-based registration and robust ICP-based registration)
to predict the intra-operative LAD vessel location based on its pre-operative loca
tion. The TRE between the actual locations of the LAD target fiducials (the ground
truth) and their predicted locations from the registration were computed for each of
the stages (Stageo, Stagei and Stage2) in the pre-operative CT images (Fig. 3.3).
Table 3.1 summarizes the overall TREs computed from two registrations between
the three stages. We can see the robust ICP-based registration outperforms weighted
landmark-based registration at all stages. Also, for a visual interpretation of the
LAD TRE, Fig. 3.4 shows the virtual model of the heart phantom along with the
gold-standard and predicted LAD paths of robust ICP-based and landmark-based
registration.
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Fig. 3.3: Graphical representation of the target registration errors of the two reg
istration techniques (robust ICP-based and Weighted Landmark-based) from peri
operative stages (Stageo, Stagei and Stage2 ) to pre-operative stage (Stagecr)40

Fig. 3.4: (a) Pre-operative heart phantom model showing the gold-standard LAD
(white); (b) Visual display of the LAD TRE (purple) from landmark-based, (c) and
robust ICP-based approach

Table 3.2: RMS Feature Localization Error (mm)
Feature Stage0 Stagei Stage2
LVAp
4.7
4.0
2.3
1.2
AVA
1.3
1.4
1.5
MVA
0.6
1.9
1.1
4.0
2.1
CO
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3.4 Discussion
This work constitutes the first steps towards optimizing pre-operative planning for
RA-CABG procedures. Motivated by a recent clinical study that revealed substantial
migration of the heart during the peri-operative procedure workflow, our goal is to
predict the intra-operative location of the target vessel, to provide the surgeon with
an optimized surgical plan that better reflects the intra-operative stage. As a bridge
to the in vivo validation, considering the limitations arising due to poor visualization
and identification of the LAD coronary vessel in clinical US images, the in vitro
phantom study was performed to assess the accuracy of two proposed registrations:
weighted landmark-based registration and robust ICP-based registration.
Both registration techniques were used to predict the peri-operative LAD location
at each pose in the workflow; according to the TRE computed along the LAD, the
robust ICP-based approach outperformed the landmark-based approach, leading to
an overall RMS TRE of 2.6 mm versus 4.6 mm, respectively (see Table 3.1). From
the results, the trend of higher errors closer to the apical end of the LAD was observed
in the weighted landmark-based registration while the robust ICP-based registration
stays relatively consist ant. This observation is mainly due to the nature of the reg
istration as the weighted landmark-based approach was limited to the use of four
landmarks for registration, while the robust approach used the complete geometry
of the features of interest for registration. The RMS FRE between the predicted
location of four features and the gold-standard location from CT was computed, and
Table 3.2 includes a summary of the RMS localization error assoicated with the
identification of each of the four features used to drive the weighted landmark-based
registration: LCO, LVAp, MVA and AVA. As observed, the point-based localization
of the LVAp and the LCO was consistently challenging, mainly due to the 2D na
ture of the US images used to identify a 3D structure and the development of the
robust ICP-based registration minimized the inconsistency of the point localization
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very well.
Nevertheless, considering that the anastomosis is performed two thirds of the way
from the left coronary ostium toward the apex, the RMS TRE on point 5 were 2.7
mm and 4.5 mm for the robust ICP-based and the weighted landmark-based approach
respectively. While the clinically tolerable error is on the order of 10-15 mm, the
accuracy provided by the proposed techniques is well within the allowable boundaries
in the in vitro experimental setting.

3.5 Conclusions
Driven by the clinical motivation to improve the pre-operative planning of RACABG procedures, here we have proposed and evaluated two registration techniques
used to predict the intra-operative target vessel locations. Our techniques were val
idated in an in vitro study simulating the clinically-observed RA-CABG procedure
workflow. The robust ICP-based registration yielded a 2.6 mm RMS TRE while the
weighted landmark-based registration yielded 4.6 mm, suggesting that the use of the
full extent of the selected features led to a better accuracy and consistancy in predict
ing the LAD location. As the validation is limited to the in vitro study, our technique
is needed to be evaluated in more clinical setting in order to strengthen its validity
to be used clinically.
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Chapter 4
Clinical Application and Validation

4.1 Introduction
Although the in vitro study provided a good evaluation of the accuracy of the
registration algorithm, the apparatus was still deemed inadequate in ensuring that
the study fully simulated an actual RA-CABG. Therefore, there was a need to perform
another validation study in a clinical setting. This chapter presents a validation study
based on the offline patient data which were acquired from RA-CABG procedure.

4.2 M aterials and M ethods
As a follow-up of the in vitro validation, a clinical validation was conducted for
further assessment of the registration. Although there is a limitation that the target
vessel is not identifiable in US images, in vivo animal experiments involve complex
interventions such as lung deflation and chest insufflation which might cause prema
ture loss of the subject prior to the end of the procedure. Therefore, a validation
study was conducted using offline data acquired from four patients who had under
gone RA-CABG and the Monte Carlo simulation method was used to estimate the
maximum TRE at the LAD.
44

4.2.1 Image Acquisition
For each patient, a pre-operative CT and three-stage peri-operative US images
were acquired as described in 3.2.1.1. A pre-operative CT was acquired prior to the
RA-CABG surgery as a routine of the patient care as well as for the pre-operative
surgical planning purpose. During the surgery, three different interventions to the
patients have been made to ensure an adequate workspace inside the chest cavity —
Stageo - after intubation and anaesthesia, Stagei - after left lung deflation, Stage2
- after chest insufflation. A magnetically tracked TEE was employed to acquire the
anatomical features of the heart at each stage of the interventions. Following image
acquisition, the four anatomical features were extracted by an expert anaesthetist,
while LAD was segmented only from CT image. Like the feature extraction in the
in vitro study, the AVA and the MVA were delineated as “ring” while the LCO was
delineated as a single point. The apical region was extracted as a paraboloid shape
which consists of a cloud of the points. Peri-operative features at each stage were
registered to the pre-operative stage by robust ICP-based registration, which was
shown to be superior to the landmark-based registration approach.

4.2.2 Assessing Target Vessel Location
For the in vitro study, the accuracy of the proposed registration algorithms in
predicting the intra-operative LAD vessel location was assessed as the TRE computed
along the LAD. However, since the gold-standard location of the LAD could not be
identified from the US images, we resorted to computing the FRE of the features of
interest and conducting a series of simulations to estimate the TRE at the LAD based
on the FRE computed above.
Given that the LAD branches off at the left coronary ostium and toward the apex
of the heart, in the simulation study, the displacement of the LAD was constrained by
the displacement of these two features. As the FRE of these features were computed,
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the maximum TRE at the LAD can be estimated and assessed against the clinically
tolerable error (10-15 mm).
4.2.2.1 Simulation Study
A simulation study was conducted using the Monte Carlo method. The shape of
the LAD was delineated from each patient’s CT data and the vessel was defined as
14 sequential points (Fig. 4.1a). For peri- to pre-operative stage registration, the
computed maximum FRE of the LCO and LVAp was used as boundary conditions for
the simulations. The displacement for the superior end of the LAD (closely located to
the LCO) was bounded by the maximum FRE of the LCO, while the displacement for
the inferior end of the LAD (closest to the LVAp) was constrained by the maximum
FRE of LVAp. The peri-operative migration patterns of the LAD were modeled
as a rigid-body transformations consisting of a translation and rotation component.
Since the purpose of this study was to estimate the “maximum” TRE at the LAD,
the translation was randomly generated, while ensuring both ends of the LAD were
inelastically constrained at the maximum boundaries set by the FRE at the LCO
and LVAp. Considering the curvature of the LAD across the surface of the heart,
the rotation component was approximated as a rotation about an axis defined by
the superior and inferior ends of the LAD with a ramdonly generated angle within a
range of 30 degrees (Fig. 4.1b).

4.2.3 M easuring Changes in Heart Position
Following the clinical validation, the migration patterns of the heart during RACABG were measured. As the LAD is not visible on intra-operative US images, it is
not feasible to measure the shift of the LAD directly. Therefore, with the assumption
that the heart does not deform significantly during the RA-CABG procedure and the
heart is treated as a rigid structure, the migration paterns of the whole heart would
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A

b)
Fig. 4.1: (a) LAD extracted from patients CT data (b) LAD with the axes of rotation,
be a good estimate of that of the LAD.
Prior to the registration, three stages of intra-operative US images as well as pre
operative CT images were acquired. US images are then transferred into the CT
image space by aligning homologous features identified during the first peri-operative
dataset (Stageo) and the pre-operative dataset (Stagecr). These two stages are physi
ologically equivalent, considering the same patient position and dual-lung ventilation,
and therefore minimal anatomical variations are expected between them. As a re
sult, heart displacement induced by the interventions can be measured with respect
to the principal body axes in the CT coordinate system. The robust ICP-based
registration was employed to corresponding source and target images to estimate the
displacements of the heart at each stage (Stagei and Stage2 ) from its original location
(Stageo).
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Table 4.1: Maximum FRE of four features (mm) — AVA, MVA, LCO, LVAp —
employed in clinical validation
Stages to CT Stage0 Stagei Stage2
3.1
0.6
LCO
1.6
5.6
MVA
4.3
1.7
1.6
3.2
6.0
AVA
1.1
LVAp
3.7
5.1

4.3

R esults

4.3.1 Clinical Validation R esult
We conducted a clinical validation based on the offline patients data to validate
the proposed registration in a more clinically representative fashion. Pre-operative
CT and peri-operative US images of four patients undergoing RA-CABG were ac
quired and the AVA, MVA, LCO and LVAp were extracted. The robust ICP-based
registration was employed to register the peri-operative stages to their pre-operative
couterpart. Table 4.1 summarizes the overall FRE of the features employed in the
registration.
Moreover, the results of simulation study are shown in Fig. 4.2. The simulations
were conducted using the Monte Carlo method and were used to estimate the TRE
at the LAD following the peri- to pre-operative registration, using the maximum
FRE of LCO and LVAp respectively. A total of 10,000 runs was conducted for each
simulation.

4.3.2 R esult of M easuring Heart Shift
The result is based from six patients who underwent RA-CABG procedure. Ta
ble 4.2 showed the magnitude of the displacement of the heart during interventions
— Stage0 - after intubation, Stagei - after left lung deflation, Stage2 - after chest
insufflation, with respect to the principal body axes in the CT coordinate system.
Also, Fig. 4.3 gave the graphical representation of these changes.
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Fig. 4.2: Estimated RMS TRE of the LAD from Monte Carlo simulations which were
conducted for each peri-operative stage

Table 4.2: Displacement of the heart with respect to the principal body axes in the
CT coordinate system for Stageo to Stagei, Stageo to Stage2 , Stagei to Stage2 (mm)
Workflow
Stage0 to Stage! Stage! to Stage2 Stage0 to Stage2
-4.4
12.8
Left/Right
14.3
11.9
9.3
Anterior/Posterior
-1.4
-6.4
1.3
0.4
Superior/ Inferior
12.1
17.5
14.4
overall
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Fig. 4.3: Graphical representations of the peri-operative heart shift during RA-CABG
procedure: (a) after intubation and anaesthesia (red) (b) after left lung deflation
(purple), and (c) after chest insufflation with CO2 (green)

4.4 Discussion
Although the in vitro study showed that the robust ICP-based registration yields
a reasonable peri- to pre-operative registration accuracy, its performance still needs to
be evaluated in a more clinically relevant scenario. As a result, patient data acquired
during four RA-CABG patients were used for another validation study. The major
limitation of clinical data is that the target vessel cannot be identified due to the poor
image quality of the peri-operative US images, which in turn impedes the estimation
of the TRE between the predicted and true target vessel. To bypass this issue, a
simple Monte-Carlo method simulation was conducted. The LAD is anatomically
bounded by the LCO at its superior end and the LVAp at its inferior end. Since
the FRE of these features can be estimated from the registration, these values were
used to constrain the maximum displacement of the LAD at its two ends during
the simulation. For each peri-operative stage, the maximum TRE of the LAD was
estimated through the simulation which is shown in Fig. 4.2. Considering the typical
anastomosis site is located two thirds of the way along the LAD from its superior end,
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the maximum TRE achieved at this site was 4.1, 4.9, and 3.4 mm for Stageo, Stagei
and Stage2 , respectively. Recalling that the purpose of the simulation study was to
examine whether the TRE of the LAD exceeded the given clinical tolerance (10 15 mm), these results confirmed that the robust ICP-based registration provide an
adaquate performance in registering the peri- to pre-operative dataset, yielding a less
than 5 mm clinical registration accuracy.
Recalling that the conversion from RA-CABG to conventional CABG might be
caused by an inaccessible target vessel due to inappropriate port placement, it is
important for the success of the procedure to correctly estimate the intra-operative
location of the heart. Since there has not been any literature reported related to the
migration patterns of the heart during RA-CABG, our preliminary results provide
a glimpse of intra-operative heart motion detection which needs to be further inves
tigated. The displacements of the heart were observed in terms of principal body
axis from the starting location (Stageo) to stages after each interventions (Stagei and
Stage2 ) as shown in Table 4.2. A big shift, 14.3 mm, to the left was observed from
Stage0 to Stagei because of the collapse of left lung deflation. Once the chest is in
sufflated with CO2 , the heart was shifted 9.3 mm to anterior, 4.4 mm to right and 6.4
mm to inferior in 3D space. Thus, the overall displacements from Stageo to Stagei
and Stage2 were measured as 14.4 mm and 17.5 mm respectively. Although this is a
preliminary result from six patients, the overall displacements could be noteworthy
because it showed that the heart could be shifted more than one intercostal space
during peri-operative interventions, which might impact on the selection of the port
placement based solely on the pre-operative CT. Therefore, it may assist in selecting
an appropriate port placement if the estimatation of the heart shift could be updated
into the pre-operative surgical planning.
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4.5 Conclusions
This chapter evaluated the system which registers intra-operative US images into
pre-operative CT images using the robust ICP-based algorithm as well as Monte Carlo
simulations in a clinical validation. The results demonstrated a maximum estimated
TRE within 5.0 mm at the site of anastomosis, which is within the clinically allowable
error for the intended application. Moreover, they document the migration patterns
of the heart, induced by left lung deflation and chest insufflation during the procedure
with displacements of 14.4 mm and 17.5 mm from the starting position to position
after left lung deflation and chest insufflation, respectively.
Although the system satisfies clinical needs, limitations remain which need to
be overcome in order for this system to be implemented in the actual RA-CABG
procedures. These will be discussed in the next chapter. Nevertheless, the work
presented in this chapter is a step forward towards port placement optimization in
RA-CABG procedures and may eventually lead to a reduction in the number of
conversions to conventional open thoracic surgery for RA-CABG procedures.
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Chapter 5
Conclusions and Future Research
In the sections below we sumarize the thesis contributions, give conclusions and
point to future research possibilities.

5.1 Contributions
Much research has been conducted to overcome a chief limitation of off-pump RACABG, which is the conversion to median sternotomy. However, most of this work
has tried to solve the problem at the pre-operative stage with the pre-operative CT
scan, thus not taking into account any peri-operative changes of the heart. Because
the patient undergoes two interventions, left lung deflation and subsequent chest
insufflation, to ensure an adaquate space inside the thoracic cavity peri-operatively,
the peri-operative shifts of the heart should be monitored and be taken into account
during pre-operative surgical planning.
The work presented in this thesis contributes to the first step towards investigating
the peri-operative motions of the heart during off-pump RA-CABG procedure. Mag
netically tracked TEE was employed to acquire images of the heart peri-operatively
while CT was acquired pre-operatively. The typical target vessel for off-pump RACABG is the LAD but identification of this target vessel using TEE often failed due
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to the limited depth penetration of TEE probe. Therefore, registrations using four
anatomical features, i.e. the weighted landmark-based and the robust ICP-based reg
istrations, were developed to register peri-operative stage images into pre-operative
stage images. These algorithms enable the displacement of the target vessel or heart
to be visualized at each intervention during the RA-CABG procedure. To evaluate
the registrations, an in vitro as well as clinical validations were conducted. In the in
vitro study, the beating heart phantom with six fiducals that trace the path of the
LAD was employed while the offline data from patients who underwent off-pump RACABG were used in the clinical validation. Bearing in mind that the peri-operative
location of the target vessel cannot be found using current imaging modalities, sim
ulations were run to deduce the maximum TRE of the LAD following the clinical
validation.
Since two validation studies yielded positive results, the displacements of the heart
at each intervention were estimated. These results show that the heart migrated more
than one intercostal space for both interventions and suggest that this peri-operative
shift of the heart should not be ignored during the pre-operative planning stage but
rather should be adapted in order to achieve a better procedural outcome.

5.2 Future Direction
In the subsections below we describe some avenues for future work.

5.2.1 M easuring heart deform ation
The project described in this thesis has been conducted based on the assump
tion that the heart does not deform significantly during the procedure with Linte et
al. [109] reporting that the valvular structures of the heart did not deform much dur
ing off-pump RA-CABG. It still, however, raises questions both from clinicians and
researchers about the degree of deformation of the whole heart during the procedure,
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Fig. 5.1: Standard 2D view and 3D rendered view of the heart using Philips real time
3D TEE transducer and iE33 scanner
yet it has not been reported in any studies.
To examine the peri-operative deformation of the heart, the only available imaging
modality currently used in the OR is the intra-operative TEE. However, the probe
employed in our project was limited with its 2D dimensionality, therefore the wall
of the left ventricle was not displayed well, which is a crucial landmark in order to
see the deformation. Since iE33 ultrasound (Philips, Andover, MA) provides a 3D
visualization, it can be used to acquire the images of the heart at each stage of the
intervention in RA-CABG (Fig. 5.1).
Once the degree of deformation is measured, it can then be integrated with the
registration to compute a more accurate displacement of the target vessel during
off-pump RA-CABG.
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5.2.2 U pdate migration patterns of the heart into the pre
operative surgical planning
From a broader perspective, this work is aimed at improving surgical planning,
as well as reducing the conversion to conventional open thoracic surgery by better
predicting the intra-operative location of the LAD during the pre-operative planning
stage, so that an optimal port placement can be identified. Since the intra-operative
locations of the LAD should be updated in the pre-operative stage, the TEE cannot
be used to find its locations and they have to be “predicted” based on the pre
operative CT. The prediction of the location of the LAD could be accomplished
using a statistical atlas. An atlas is a set of CT images that incorporates different
information. In our case, an atlas consists of CT images of patients who underwent
the RA-CABG procedures to contain the heart migration patterns and intra-operative
LAD locations. Since the migration pattern would be different because of the sex,
shape of rib cage or weight, it is important to select an appropriate subset of CT
images from the atlas for the best results. Therefore, when a new patient undergoes
the RA-CABG procedure, the CT images of the patient are acquired so as to select
the right subset of CT according to a specific classification from CT atlas, similar to
the one employed by Aljabar et al [124].
Once a patient specific subset is constructed, the intra-operative surgical target
location can be “predicted” by registering this subset of the atlas to the patient’s CT
scan.

5.2.3 R eal-tim e update of the location of the target vessel
Another way to find the optimal port placement in a RA-CABG procedure is to
provide a real-time update of the location of the target vessel. However, under the
current protocol of RA-CABG, the US image acquisition at each pose in the workflow
is conducted during the procedure, while all feature identification and registration is
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performed off-line. Although registration can be performed in nearly real-time, the
major drawback is feature extraction, which takes several minutes to complete, leading
to difficulties in segmenting the required features in real time during a procedure. To
perform real-time registration, automated feature segmentation is necessary and our
lab is currently working on the development of automatic segmentation techniques
for the left ventricle and valvular structures. When accurate registration is followed
by the ability to perform automatic segmentation in real-time, the updated location
of the target vessel can be fused into the 3D stereo endoscopic camera in the da Vinci
surgical system to find an optimal port placement.

5.2.4 Extension to other types of surgery
The techniques presented in this thesis could be employed in other types of min
imally invasive cardiac surgeries. Minimally invasive mitral valve repair and atrial
septal defect repair are potential procedures in which this technique could be used.
While off-pump RA-CABG has two interventions, such as left lung deflation and
chest insufflation, mitral valve repair and atrial septal defect repair require only lung
deflation (mitral valve repair - left lung, atrial septal defect repair - right lung). The
target feature for mitral valve repair is the mitral valve annulus, while the septum
should be identified for atrial septal defect repair. Since those features are already
identified as anatomical features in our technique or can be easily identified, the pro
posed technique can be implemented into these two cardiac surgeries to provide an
updated intra-operative location of the surgical target for the surgeon, to achieve a
better procedural outcome.

5.3

Conclusion

Since the first successful revascularization surgery was performed in 1957, CABG
has evolved to improve the efficacy, as well as the safety of the procedure. RA57

CABG is a very recent technology which minimizes the invasiveness of CABG and
reduces the patient’s discomfort during the procedure in addition to length of hospital
stay. Because this technology is new and still results in a substantial conversion to
conventional open-thoracic CABG, more research must be conducted in order to adopt
RA-CABG as a primary treatment option for patients who need revascularization
surgery. We hope that the work described in this thesis may contribute to improving
the outcome of the RA-CABG procedure.
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Appendix A
Solutions for least-square
estimation problem

A .l Singular value decom position
Algorithm 1 SVD solution
1: H = sum of p q
2: U A V T is the SVD of H
Z: X = V U T

4: if determinant of X — 1 then
5: R = X

6: end if

A .2 H orn’s m ethod using unit quaternions
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Algorithm 2 Horn’s method using unit quaternions
+ Syy +
Syz — Szy
Syz — Szy

W

2: Where

Sxx — Syy — Szz

Szx — Sxz

Sxy

Sxy — Syx

Szx

+ Syx
+ Sxz

Szx — Sxz
Sxy

Sxy — Syz

+ Syx

+ Sxz
Syz + Szy
S z z — S x x —S y y
Szx

Syy — S xx - Szz
Syz + Szy

sum (P(i,«9«, 1 ))
sum (p(<il)i(i)2))
sum (p(jil)g(ji3))
sum (p(i>2)9(i,i))
Syy

8:

Syz
Szx

= sum(p(W)i«,2))
= sum(p(ii2)9(i,3))
= sum(p(i>3)9(i>1))

10: S z y = sum(p(ii3)(j(ij2))
Szz

= sum(p(ji3)5 (<j3))

12: V = eigenvectors of W
m = eigenvector corresponding to maximum eigenvalue
14: if the largest value of m < 0 then

m = m * —1
16: end if
m\ + 7712 rrio —m 2 (m27773 + 77127774)
R
2(77727773 —77717774) 777^ + 7773 —7772 —m 4
2 ( t7727774 + 777x7773)

2(77737774 — 777i 7772)
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2(77727774 — 777x7773)
2(77737774 + 777i 7772)
777i + 7774

Tile

Til'.

Appendix B
Pseudo code for Robust ICP
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Algorithm 3 Robust ICP using Tukey’s biweight
P = source points
Q = target points
3: S = scale
{zi} = set of residual errors between P and X
Pold OO
6- Pnew = P i^i)
while |pnew ~ Poid\ > tolerance do
C = med{£j} * 1.4826
9: if \zi\ < med{^} then
Wi (z) = [l - (z/ (c + m ed\zi\)f]2
else
12:
Wi (z) = 0
end if
use P, A, {wi} and Horn’s method to find a new R and t
15: newP = R (P) + t
{z^ = set of residual errors between newP and X
Pold Pnew
18: pnew = P C^*)
end while
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